Mylan reports lower than expected earnings

North America segment net sales were down 18% to $4.10 billion, which the company said was partly driven by the restructuring and remediation activities at the Morgantown, West Virginia plant. In November the FDA warned Mylan about “significant” manufacturing violations at the plant, including “inadequate” cleaning of equipment and a failure to thoroughly investigate batches of medicines that did not meet specifications.
Read more...

;